The lawsuit claims Procept BioRobotics misled shareholders by concealing an incentive program that pushed customers to purchase handpiece units far beyond actual procedure demand. This strategy allegedly created a glut of more than 10,000 excess units in field inventory, artificially boosting reported revenues while pulling future sales into the present. According to the complaint, these practices left the company unable to meet its 2025 financial guidance, causing significant losses for investors when the discrepancies surfaced.
In section Releases
Investors Face September Deadline in Procept BioRobotics Securities Suit
Investors who purchased PROCEPT BioRobotics common stock between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek lead plaintiff status in an ongoing securities fraud lawsuit. The action follows allegations that the company artificially inflated sales figures through undisclosed bulk-order discount programs.
Rosen Law Firm, which is representing the plaintiffs, notes that while a class-action suit has been filed, no class has been certified yet. Investors are not required to take action to participate in a potential future recovery, but those wishing to serve as a lead plaintiff must file their motion with the court by the September deadline. The firm advises that investors may select their own counsel or choose to remain absent members of the class.
Comments (0)
No comments yet. Be the first!